First Light Asset Management LLC Sells 161,683 Shares of AtriCure, Inc. $ATRC

First Light Asset Management LLC reduced its position in AtriCure, Inc. (NASDAQ:ATRC) by 22.2% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 567,838 shares of the medical device company’s stock after selling 161,683 shares during the period. AtriCure accounts for approximately 1.0% of First Light Asset Management LLC’s investment portfolio, making the stock its 28th largest holding. First Light Asset Management LLC’s holdings in AtriCure were worth $15,888,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of ATRC. Smartleaf Asset Management LLC grew its holdings in shares of AtriCure by 59.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock worth $46,000 after acquiring an additional 429 shares during the period. Scotia Capital Inc. lifted its holdings in AtriCure by 1.2% in the third quarter. Scotia Capital Inc. now owns 37,677 shares of the medical device company’s stock valued at $1,328,000 after acquiring an additional 457 shares during the period. ProShare Advisors LLC boosted its position in AtriCure by 6.6% in the fourth quarter. ProShare Advisors LLC now owns 8,819 shares of the medical device company’s stock worth $349,000 after purchasing an additional 543 shares during the last quarter. Captrust Financial Advisors boosted its position in AtriCure by 7.9% in the fourth quarter. Captrust Financial Advisors now owns 7,944 shares of the medical device company’s stock worth $314,000 after purchasing an additional 579 shares during the last quarter. Finally, Mackenzie Financial Corp grew its stake in shares of AtriCure by 5.3% during the 4th quarter. Mackenzie Financial Corp now owns 13,597 shares of the medical device company’s stock valued at $545,000 after purchasing an additional 683 shares during the period. Institutional investors own 99.11% of the company’s stock.

AtriCure Stock Performance

NASDAQ:ATRC opened at $53.03 on Thursday. The stock has a 50-day simple moving average of $41.54 and a two-hundred day simple moving average of $33.26. AtriCure, Inc. has a 52-week low of $25.36 and a 52-week high of $55.72. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. The firm has a market capitalization of $2.70 billion, a PE ratio of 252.54 and a beta of 1.26.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.The business had revenue of $153.60 million during the quarter, compared to analysts’ expectations of $151.80 million. During the same quarter in the prior year, the business posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Analysts forecast that AtriCure, Inc. will post 0.29 EPS for the current year.

Insider Activity at AtriCure

In related news, insider Salvatore Privitera sold 7,763 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $52.50, for a total value of $407,557.50. Following the completion of the sale, the insider directly owned 150,921 shares of the company’s stock, valued at approximately $7,923,352.50. This represents a 4.89% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Vinayak Doraiswamy sold 6,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $38.88, for a total transaction of $233,280.00. Following the sale, the insider owned 86,511 shares in the company, valued at approximately $3,363,547.68. The trade was a 6.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 61,379 shares of company stock worth $2,557,552 in the last quarter. 4.00% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. BTIG Research upped their price target on shares of AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Monday, August 24th. Citigroup reissued a “market outperform” rating on shares of AtriCure in a report on Tuesday, July 21st. Raymond James Financial set a $52.00 target price on shares of AtriCure in a research report on Tuesday, July 21st. Piper Sandler upped their target price on shares of AtriCure from $50.00 to $60.00 and gave the company an “overweight” rating in a report on Thursday, August 27th. Finally, Zacks Research downgraded shares of AtriCure from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 24th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, AtriCure currently has a consensus rating of “Moderate Buy” and a consensus price target of $52.00.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.